Palmitoyl pentapeptide-4

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Laboratory permeation research found that palmitoylation changed peptide stability and skin transport, while full-thickness permeation remained limited under the tested conditions. Such work informs delivery uncertainty rather than proving benefit.[3]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Cosmetic / topical

  Palmitoyl pentapeptide-4 is used in cosmetics. Cosmetics generally are not FDA-approved before marketing, and no therapeutic FDA approval was identified.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• Acetyl octapeptide-3Both are topical cosmetic peptides with limited formulation-specific human evidence.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   FDA UNII record for palmitoyl pentapeptide-4

   U.S. Food and Drug Administration Global Substance Registration System. Palmitoyl pentapeptide-4 (KK181SM5JG) substance record.

   U.S. Food and Drug Administration · Accessed Jul 22, 2026 · Regulatory source

   Open source
2. 2

   Topical palmitoyl pentapeptide study in photoaged skin

   Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160.

   PubMed-indexed primary study · Published Jun 1, 2005 · Accessed Jul 22, 2026 · Clinical study

   Open source
3. 3

   Dermal stability and permeation study of KTTKS and pal-KTTKS

   Choi YL, et al. Dermal stability and in vitro skin permeation of collagen pentapeptides. Biomolecules and Therapeutics. 2014;22(4):321-327.

   PubMed-indexed primary study · Published Jul 1, 2014 · Accessed Jul 22, 2026 · Preclinical study

   Open source
4. 4

   FDA authority over cosmetics

   U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated.

   U.S. Food and Drug Administration · Published Dec 20, 2022 · Accessed Jul 22, 2026 · Regulatory source

   Open source